Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (DE:3ZO)
FRANKFURT:3ZO
RESEARCH TOOLSreports
Holding DE:3ZO?
Track your performance easily
3ZO Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.67 - €4.28
Previous Close€0.77
Volume0.00
Average Volume (3M)2.00K
Market Cap
€13.36M
Enterprise Value€7.84M
Total Cash (Recent Filing)$5.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.76
Next Earnings
Mar 13, 2025EPS Estimate
-€0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,892,548
10 Day Avg. Volume0
30 Day Avg. Volume2,000
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.81
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.48
Forecast
1Y Price Target
€10.61Price Target Upside1280.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Acurx Pharmaceuticals News
PremiumCompany Announcements
Acurx Pharmaceuticals Reports Promising Q3 2024 Results
Options Prices
Currently, No data available
---
Ownership Overview
12.91% Insiders
3.84% Mutual Funds
1.93% Other Institutional Investors
78.19% Public Companies and
Individual Investors
3ZO FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was €0.67 and its highest was €4.28 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Currently, no data Available
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Nov 13, 2024. The company reported -€0.163 earnings per share for the quarter, missing the consensus estimate of -€0.139 by -€0.024.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -€0.17.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 16,892,548 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -€0.163 in its last earnings report, missing expectations of -€0.139. Following the earnings report the stock price went up 1.056%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3ZO
---
Acurx Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.61 (1280.17% Upside)
€10.61 (1280.17% Upside)
Blogger Sentiment
Bullish
DE:3ZO Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.42%
12-Months-Change
Fundamentals
Return on Equity
-498.16%
Trailing 12-Months
Asset Growth
-16.42%
Trailing 12-Months
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
---
3ZO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory readiness, which are promising for future developments. However, financial challenges and the need for funding to proceed with Phase III trials pose risks.Read More>---
3ZO Stock 12 Month Forecast
Average Price Target
€10.61
▲(1280.17% Upside)
Technical Analysis
Acurx Pharmaceuticals
―
Atea Pharmaceuticals
―
Chimerix
―
Aurinia Pharmaceuticals
―
Acura Pharmaceuticals
―
Best Analysts Covering 3ZO
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-30.34%
reiterated a buy rating 13 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -30.34% per trade.
---